Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer

BACKGROUND: First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, show...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Miyo, Masaaki, Kato, Takeshi, Yoshino, Takayuki, Yamanaka, Takeharu, Bando, Hideaki, Satake, Hironaga, Yamazaki, Kentaro, Taniguchi, Hiroya, Oki, Eiji, Kotaka, Masahito, Oba, Koji, Miyata, Yoshinori, Muro, Kei, Komatsu, Yoshito, Baba, Hideo, Tsuji, Akihito
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7376863/
https://ncbi.nlm.nih.gov/pubmed/32703200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07186-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados